Back to top
more

Elanco Animal Health (ELAN)

(Real Time Quote from BATS)

$13.34 USD

13.34
1,484,987

+0.30 (2.30%)

Updated Apr 26, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 252)

Industry: Medical - Outpatient and Home Healthcare

Better trading starts here.

Zacks News

Boston Scientific's (BSX) Watchman US Sale to Aid Q1 Earnings

Within Boston Scientific's (BSX) coronary therapies, drug-eluting stents sale continue to be a challenge from a pricing standpoint in Q1.

Integra (IART) to Report Q1 Earnings: What's in the Offing?

The acquisition of ACell, and faster recovery growth rate in Japan and China are likely to have helped recover Integra's first-quarter 2021 performance.

VITUS to Hurt Chemed (CHE) Q1 Earnings, Roto-Rooter to Aid

The federal government's recent approach in terms of relaxing regulations, allowing broader use of telehealth, is likely to have helped in some sort of recovery of Chemed's (CHE) VITAS business in Q1.

Amedisys (AMED) to Report Q1 Earnings: What's in Store?

Growth in Home Health and Hospice along with recent innovation and acquisitions is expected to have contributed to Amedisys (AMED) top-line growth in Q1.

Molecular Tests to Drive Quest Diagnostics (DGX) Q1 Earnings

Through the first quarter, Quest Diagnostics' (DGX) several significant strides in the field of COVID-19 diagnostic testing are expected to have contributed to the top line.

Demand for Nutrition Line to Drive Abbott (ABT) Q1 Earnings

Two additional regulatory approvals in Europe are expected to have widened Abbott's (ABT) global Panbio customer base through Q1, contributing to the top line.

Why Elanco Animal Health Incorporated (ELAN) Might be Well Poised for a Surge

Elanco Animal Health Incorporated (ELAN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Elanco Animal Health Incorporated (ELAN) Q4 Earnings and Revenues Beat Estimates

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 33.33% and 8.48%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Elanco Animal Health Incorporated (ELAN) Q4 Earnings Expected to Decline

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

New Strong Sell Stocks for January 5th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Elanco Animal Health Incorporated (ELAN) Tops Q2 Earnings and Revenue Estimates

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of 350.00% and 5.48%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Elanco (ELAN) Ahead of Earnings?

Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Estimate Elanco Animal Health Incorporated (ELAN) to Report a Decline in Earnings: What to Look Out for

Elanco Animal Health Incorporated (ELAN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bayer Initiates a Phase III Study in Heart Failure Patients

Bayer (BAYRY) initiates a phase III study to evaluate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction.

Bayer (BAYRY) Submits Applications for Heart Failure Drug

Bayer (BAYRY) seeks approval of chronic heart failure drug, vericiguat, in the EU and Japan.

Elanco Animal Health Incorporated (ELAN) Q1 Earnings and Revenues Miss Estimates

Elanco Animal Health Incorporated (ELAN) delivered earnings and revenue surprises of -45.83% and -9.94%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for Elanco (ELAN) This Earnings Season?

Elanco (ELAN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Elanco Animal Health Incorporated (ELAN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Elanco Animal Health Incorporated (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bayer (BAYRY) Q1 Earnings Beat Estimates, Sales Rise Y/Y

Bayer (BAYRY) beats earnings estimates for the first quarter of 2019.

Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Rise Y/Y

Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2019.

New Strong Sell Stocks for February 11th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Elanco (ELAN) Surges: Stock Moves 5.3% Higher

Elanco (ELAN) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

New Strong Sell Stocks for January 14th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zoetis Surges 45.3% YTD on Strong Portfolio & New Approvals

Zoetis (ZTS) surges on strong performance year to date, backed by a solid portfolio and prudent acquisitions.

Zoetis (ZTS) Acquires ZNLabs to Bolster Diagnostics Portfolio

Zoetis (ZTS) acquires ZNLabs and expands its reference laboratory capabilities in the United States.